Search
Denufosol
go.drugbank.com/drugs/DB04983InvestigationalA new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking denufosol. … Denufosol was an inhaled drug used for the treatment of cystic fibrosis (CF), showing various improvements in lung function during a phase III clinical trial.
Categories: Heterocyclic Compounds, 1-RingSplicing factor 3B subunit 3
go.drugbank.com/bio_entities/BE0009020TargetHumansThe 17S U2 SnRNP complex (1) directly participates in early spliceosome assembly and (2) mediates recognition of the intron branch site during pre-mRNA splicing by promoting the selection of the pre-mRNA … Also acts as a component of the minor spliceosome, which is involved in the splicing of U12-type introns in pre-mRNAs (PubMed:15146077, PubMed:33509932)
Synonyms: Pre-mRNA-splicing factor SF3b 130 kDa subunitCretostimogene grenadenorepvec
go.drugbank.com/drugs/DB05148InvestigationalCG0070 is a solid. CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF.
BBV152
go.drugbank.com/drugs/DB15847InvestigationalBBV152 is a vaccine candidate created by the Indian Council of Medical Research (ICMR). … or a novel TLR7/8 agonist adsorbed gel.
Synonyms: Whole-Virion Inactivated SARS-CoV-2 VaccineRozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigational[L47122] It was granted orphan drug designation by the FDA in 2019, by the European Medicines Agency (EMA) in April 2020, and by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November … Rozanolixizumab is a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P) targeting the immunoglobulin G (IgG).
Products: Rystiggo 280 mg/2 ml Enjeksiyonluk Çözelti, 1 adetSarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationalSeysara (sarecycline) was originally part of Allergan's US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the … s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients
Categories: P-glycoprotein inhibitorsTozinameran
go.drugbank.com/drugs/DB15696ApprovedInvestigational2 months. … [A225386] Comirnaty was granted a EUA in the UK on December 2, 2020,[L26676] and in Canada on December 9, 2020[L26671] for active immunization against SARS-CoV-2.
Mixtures: Comirnaty Original & Omicron Ba.4/ba.5, Comirnaty Original & Omicron Ba.4/ba.5Fidanacogene elaparvovec
go.drugbank.com/drugs/DB16783ApprovedInvestigationalfrom week 12 to month 15 compared to an ABR of 4.43 for the pre-treatment period. … [L46691] Hemophilia B is a rare X-linked genetic disorder characterized by abnormal coagulation due to dysfunctional coagulation factor IX with a male incidence estimated to be 1 in 30,000 male births
Pemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigational[A198963] The FDA-approved indication for pemigatinib was granted under accelerated approval based on the overall response rate and duration of response in pre-marketing clinical trials. … Pemigatinib is a small molecule kinase inhibitor with antitumour activity.
Categories: MATE 1 Inhibitors, Cytochrome P-450 SubstratesLasmiditan
go.drugbank.com/drugs/DB11732ApprovedInvestigationalhowever, and their vasoconstrictive activity can lead to blood pressure lability and other cardiovascular side effects - for this reason, these medications are less suitable for use in patients with pre-existing … [A187322,A187319] Selectivity for 5-HT<sub>1F</sub>, a lack of vasoconstrictive activity, and the ability to terminate migraines through neuronal inhibition has resulted in the creation of a new class
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsProducts: 1 Rayvow